Back to search results

Evaluating [18F] F-GLN by PET/CT in Breast Cancer

This study is looking at how a special imaging agent called Fluoroglutamine [18F]F-GLN (pronounced "F-G-L-N") moves through the body and collects in breast cancer. Researchers will use PET/CT scans to see how this agent behaves in both primary (original) and metastatic (spread) breast cancer. They want to understand its "kinetics" (how it moves over time) and "biodistribution" (where it goes in the body). You might be able to join if you are at least 18 years old and have known or suspected breast cancer with at least one tumor that is 1.0 cm or larger. The study aims to include up to 40 participants, with a focus on different types of breast cancer. This is an observational study, meaning the imaging results will not directly change your treatment plan.

Study design
This is an interventional study involving up to 40 participants. It is designed to observe how Fluoroglutamine [18F]F-GLN behaves in breast cancer.
What's involved
You would undergo approximately 60 minutes of dynamic PET scanning, followed by up to two static PET/CT scans after receiving Fluoroglutamine [18F]F-GLN. A baseline FDG-PET/CT scan will also be performed. Some participants may have an optional second set of scans.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, kinetics and biodistribution of [18F]F-GLN, will be measured at 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03863457

[18F] F-GLN by PET/CT in Breast Cancer

Recruiting
PHASE1Ages 18+InterventionalDiagnostic
Abramson Cancer Center at Penn Medicine
~40 participants
Updated 2026-01-22 on ClinicalTrials.gov
What's tested:Fluoroglutamine [18F]F-GLN

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Kinetics and Biodistribution of [18F]F-GLN
Measured over 3 years

Conditions

Breast Cancer

Explore related trials

Breast Carcinoma

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Austin Pantel, MD · PRINCIPAL_INVESTIGATOR · Instructor of Radiology

Who to contact

Erin Schubert
[email protected]
215-573-6569
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants will be ≥ 18 years of age
Known or suspected primary or metastatic breast cancer.
At least one lesion ≥ 1.0 cm that is seen on standard imaging (e.g. CT, MRI, mammogram, ultrasound, FDG-PET/CT). Only one type of imaging is required to show a lesion.
Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion

Females who are pregnant or breast feeding at the time of screening; a urine pregnancy test will be performed in women of child-bearing potential at screening.
Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
Any current medical condition, illness, or disorder, as assessed by medical record review and/or self-reported, that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.

What this trial measures

  • Kinetics and Biodistribution of [18F]F-GLN3 years

    Evaluate the biodistribution of \[18F\]F-GLN by measuring organ and whole body dosimetry.